Shi Yuanyuan made a speech on CGT industry development, enterprise strategic layout and positioning, enterprise construction and major breakthroughs, honors and approved projects in 2023, major strategic cooperation, and strategic goals in 2024. First of all, cell and gene therapy is the forefront of the track field, Shenzhen Cell Valley as a technology-driven enterprise, in the economic winter period, 2023 in the enterprise honor, project application, customer service, sales, scientific research results, clinical progress and other aspects of rapid development. Shenzhen-level major public service platform projects and innovation platform construction projects have received financial support from the government, and the influence of the industry has gradually expanded; Service and cooperation customers from domestic to international steady expansion, sales made a qualitative breakthrough, market channels are gradually opened, to provide more and more customers with quality products and services; Shenzhen Cell Valley's current scientific research products CAR-NK, CAR-γδT and other cell production has made a major breakthrough, to provide customers with high efficiency, high yield, high quality products.

Shenzhen Cell Valley adheres to the mission of "not forgetting the original intention, curing diseases and saving lives", uses innovative anti-BCMA CAR T cell therapy technology, and cooperates with Shenzhen 3A Hospital to successfully apply it to clinical practice, so that cancer patients can achieve VGPR efficacy and recover and leave the hospital; The commissioned CD19/CD22 dual-target CAR-T was used in a famous children's hospital in Guangzhou, which successfully treated an 8-year-old child who underwent chemotherapy and two sequential CAR-T treatments. The patient was discharged after 10 days of infusion and MRD negative after 1 month. At the same time, Shenzhen Cell Valley uses its unique production process PackRV-SS system to provide low-cost and high-quality retroviral vectors and cell products for enterprises, and has also been successfully used in clinical practice, making positive contributions to the life treatment of many patients with refractory recurrent cancer.

Shi Yuan said that in 2023, Shenzhen Cell Valley has made remarkable achievements in both external and internal construction of the enterprise, the Cell Valley team has gradually grown, the core technical personnel have steadily increased, and the management level has continuously improved, laying a solid foundation for the development of the company. Into 2024, Shenzhen Cell Valley will continue to deepen the field of cell and gene therapy with the goal of "researching and developing new technologies, forging new production, creating new formats and opening up new markets". Pay attention to industry trends, closely track cutting-edge biotechnology, continue to maintain and develop core competitiveness, increase investment in research and development, promote product innovation, improve product quality, and expand market sales to meet the changing market demand.

On the occasion of the successful conclusion of the summary conference, all the staff of Shenzhen Cell Valley joined hands to enter a new journey in 2024. "The heart is strong, hand in hand; With a mind that can be achieved, create an inheritance that is not yet available." At a new starting point, Shenzhen Cell Valley will continue to uphold the corporate vision of "cells benefit all sentient beings · Gene create the future", strive to achieve the company's strategic goals, and create new business forms in the cell and gene therapy industry!